Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progesterone receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    265 result(s) found for: Progesterone receptor. Displaying page 2 of 14.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002556-24 Sponsor Protocol Number: CLEE011XDE01 Start Date*: 2016-10-14
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A national phase IIIb, multi-center, open label study for women and men with hormone-receptor positive, HER2-negative locally advanced or metastatic breast cancer treated with ribociclib (LEE011) i...
    Medical condition: HR+, HER2- advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002114-23 Sponsor Protocol Number: BAY88-8223/17096 Start Date*: 2015-10-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus whe...
    Medical condition: Metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001559-38 Sponsor Protocol Number: GEICAM/2018-06 Start Date*: 2022-01-20
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Early-stage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Can...
    Medical condition: HER2+, HR+ Early stage Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083234 Hormone receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001110-15 Sponsor Protocol Number: 1280.4 Start Date*: 2014-04-25
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer
    Medical condition: Locally Advanced or Metastatic Breast Cancer positive for estrogen-receptor (ER) and/or progesterone receptor (PgR) and negative for HER2 which is refractory to non-steroidal aromatase inhibitor (...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) FR (Completed) BE (Completed) NL (Completed) SE (Completed) IE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001054-34 Sponsor Protocol Number: D0816C00018 Start Date*: 2018-01-11
    Sponsor Name:AstraZeneca AB
    Full Title: LUCY - Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-...
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) FR (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004869-27 Sponsor Protocol Number: MK-3475-756 Start Date*: 2019-05-03
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Es...
    Medical condition: High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005835-87 Sponsor Protocol Number: GBG41 Start Date*: 2006-08-16
    Sponsor Name:GermanBreastGroup
    Full Title: A randomized discontinuation phase II study to determine the efficacy of RAD001 in breast cancer patients with bone metastases
    Medical condition: Bone metasatsis, Breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002600-33 Sponsor Protocol Number: IBCSG 34-05/ SWOG 0230 Start Date*: 2007-02-16
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer
    Medical condition: Premenopausal women, Early Stage I, II or IIIA, ER-/ PR- Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-000073-23 Sponsor Protocol Number: CRAD001YIC04 Start Date*: 2012-05-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrin...
    Medical condition: Estrogen receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) NL (Completed) SE (Completed) NO (Completed) ES (Completed) DK (Completed) FI (Completed) BE (Completed) CZ (Prematurely Ended) IT (Completed) HU (Completed) IE (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-003467-19 Sponsor Protocol Number: CLEE011A2404 Start Date*: 2016-12-08
    Sponsor Name:Novartis Pharma AG
    Full Title: COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal wo...
    Medical condition: hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) HU (Completed) BG (Completed) PT (Completed) GR (Completed) SK (Completed) IT (Completed) CZ (Completed) AT (Completed) ES (Completed) DK (Completed) NO (Completed) PL (Completed) FI (Completed) SI (Completed) RO (Ongoing) LU (Completed)
    Trial results: View results
    EudraCT Number: 2011-006111-62 Sponsor Protocol Number: CRAD001JDE49 Start Date*: 2012-07-11
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination Wi...
    Medical condition: The trial aims to evaluate the efficacy, safety, quality of life and health resources in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with N...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003877-21 Sponsor Protocol Number: CCR2973 Start Date*: 2008-06-20
    Sponsor Name:Institute of Cancer Research [...]
    1. Institute of Cancer Research
    2. The Royal Marsden NHS Foundation Trust
    Full Title: Trial of Perioperative Endocrine Therapy - Individualising Care (POETIC)
    Medical condition: Post menopausal women with hormone (ER/PgR) receptor positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-003752-79 Sponsor Protocol Number: PIONEER Start Date*: 2017-05-24
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: Randomised Phase II clinical trial PIONEER- A Pre-operative wIndOw study of letrozole plus PR agonist (Megestrol Acetate) versus letrozole aloNE in post-menopausal patients with ER-positive breast ...
    Medical condition: ER-positive, HER2-negative, invasive primary breast cancer of at least 1 cm size
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-002707-18 Sponsor Protocol Number: EFFECT Start Date*: 2012-11-14
    Sponsor Name:FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS
    Full Title: EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed breasT cancer
    Medical condition: Patients aged 65 years or older with histologically or cytologically confirmed breast cancer, locally recurrent and/or metastatic; any estrogen/progesterone receptor status; HER2 receptor negative ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002284-18 Sponsor Protocol Number: UC-0140/1711 Start Date*: 2017-12-02
    Sponsor Name:UNICANCER
    Full Title: A randomized phase 2 study in patients with triple-negative, androgen receptor positive locally advanced (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine
    Medical condition: Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally advanced (unresectable) or metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002453-26 Sponsor Protocol Number: 73908 Start Date*: 2020-11-18
    Sponsor Name:Rigshospitalet
    Full Title: Eight weeks of androgen priming by hCG before IVF/ICSI in women with low ovarian reserve.
    Medical condition: Female Infertility
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004872 10016399 Female infertility (primary) LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002541-63 Sponsor Protocol Number: IMP321-P011 Start Date*: 2015-12-21
    Sponsor Name:Immutep S.A.S.
    Full Title: AIPAC (Active Immunotherapy PAClitaxel): A multicentre, Phase IIb, randomised, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP...
    Medical condition: Female metastasized oestrogen receptor positive and/or progesterone receptor positive breast adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) BE (Completed) HU (Completed) FR (Completed) DE (Completed) PL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-004263-35 Sponsor Protocol Number: CFEM345D2411 Start Date*: 2006-03-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer
    Medical condition: This study will be a head to head comparison of letrozole versus anastrozole in the adjuvant treatment of high risk patients. Post-menopausal patients who recently have undergone their primary surg...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) AT (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-009429-26 Sponsor Protocol Number: local 997 (P06034) Start Date*: 2010-03-15
    Sponsor Name:FREE UNIVERSITY OF BRUSSELS
    Full Title: A PILOT STUDY TO EVALUATE THE EFFECT OF TRIGGERING FINAL OOCYTE MATURATION WITH GnRHa OR hCG ON ENDOMETRIAL RECEPTIVITY PARAMETERS AND THE LUTEAL PHASE IN OOCYTE DONORS
    Medical condition: Compare the endometrium of oocyte donors, who had final oocyte maturation with either hCG, Suprefact, followed by hCG 35 hours after triggering, Suprefact or Suprefact without luteal phase support....
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004172-35 Sponsor Protocol Number: SB3-G31-BC Start Date*: 2014-02-12
    Sponsor Name:Samsung Bioepis Co., Ltd.
    Full Title: A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Hercep...
    Medical condition: newly diagnosed primary HER2 positive early or locally advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) PL (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 22 10:11:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA